Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01205217
- Locations
- 🇪🇸
GSK Investigational Site, Castellón, Spain
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 369
- Registration Number
- NCT01160211
- Locations
- 🇬🇧
Novartis Investigative Site, Sutton, United Kingdom
Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- National Center for Tumor Diseases, Heidelberg
- Target Recruit Count
- 76
- Registration Number
- NCT01145404
- Locations
- 🇩🇪
I. Med. Klinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität, Mainz, Germany
🇩🇪Klinikum rechts der Isar, München, Germany
🇩🇪NCT Heidelberg, Heidelberg, Germany
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01137994
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 19
- Registration Number
- NCT01138384
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
- Conditions
- Interventions
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 12
- Registration Number
- NCT01118975
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Lapatinib With Sirolimus or Metformin
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT01087983
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT01068704
- Locations
- 🇺🇸
Texas Oncology-Abilene, Abilene, Texas, United States
🇺🇸Texas Oncology-Beaumont, Beaumont, Texas, United States
🇺🇸Us Oncology Central Pharmacy, Fort Worth, Texas, United States
Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer
- First Posted Date
- 2010-01-08
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 17
- Registration Number
- NCT01044485
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, Bourgogne, France
Lapatinib in Combination With Vinorelbine
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT01013740
- Locations
- 🇪🇸
Novartis Investigative Site, Zamora, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.